← All trials
NCT07081503
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 14, 2025
- Primary completion
- Jan 22, 2027
- Completion date
- Jan 22, 2027
- First posted
- Jul 23, 2025
- Last posted
- Jul 23, 2025
- Enrollment
- 44
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ADARx Pharmaceuticals, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.